Research Analysts’ Weekly Ratings Updates for Exelixis (EXEL)

Several analysts have recently updated their ratings and price targets for Exelixis (NASDAQ: EXEL):

• 1/13/2025 – Exelixis had its price target raised by analysts at Piper Sandler from $36.00 to $37.00. They now have an “overweight” rating on the stock.
• 1/10/2025 – Exelixis had its price target raised by analysts at HC Wainwright from $29.00 to $40.00. They now have a “buy” rating on the stock.
• 1/7/2025 – Exelixis had its price target raised by analysts at Guggenheim from $33.00 to $42.00. They now have a “buy” rating on the stock.
• 12/23/2024 – Exelixis is now covered by analysts at Brookline Capital Management. They set a “buy” rating on the stock.
• 12/20/2024 – Exelixis was downgraded by analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating. They now have a $40.00 price target on the stock, up previously from $36.00.
• 12/17/2024 – Exelixis was downgraded by analysts at Bank of America Co. from a “buy” rating to a “neutral” rating. They now have a $39.00 price target on the stock, up previously from $35.00.

Exelixis Price Performance

NASDAQ:EXEL traded down $0.72 during trading hours on Monday, reaching $35.30. The company had a trading volume of 2,602,541 shares, compared to its average volume of 2,130,063. The business’s 50 day moving average price is $34.88 and its 200-day moving average price is $28.90. Exelixis, Inc. has a 1-year low of $20.01 and a 1-year high of $36.97. The firm has a market cap of $10.08 billion, a PE ratio of 22.63, a price-to-earnings-growth ratio of 0.88 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The business had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. During the same period last year, the company posted $0.10 EPS. The business’s revenue was up 14.3% on a year-over-year basis. On average, analysts expect that Exelixis, Inc. will post 1.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Dana Aftab sold 1,162 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the sale, the executive vice president now directly owns 498,945 shares in the company, valued at approximately $15,666,873. The trade was a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jeffrey Hessekiel sold 25,000 shares of Exelixis stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $28.39, for a total transaction of $709,750.00. Following the transaction, the executive vice president now owns 580,325 shares of the company’s stock, valued at approximately $16,475,426.75. The trade was a 4.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 314,736 shares of company stock worth $10,849,110 over the last three months. Insiders own 2.85% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of EXEL. Covestor Ltd grew its position in shares of Exelixis by 5.7% during the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 341 shares during the last quarter. Creative Planning lifted its stake in shares of Exelixis by 0.8% in the 2nd quarter. Creative Planning now owns 71,700 shares of the biotechnology company’s stock worth $1,611,000 after acquiring an additional 548 shares during the period. Advisors Asset Management Inc. increased its position in shares of Exelixis by 3.2% during the 3rd quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company’s stock valued at $515,000 after purchasing an additional 609 shares during the period. Signaturefd LLC raised its stake in shares of Exelixis by 12.2% in the 3rd quarter. Signaturefd LLC now owns 6,138 shares of the biotechnology company’s stock worth $159,000 after buying an additional 666 shares in the last quarter. Finally, Vestcor Inc boosted its stake in Exelixis by 1.2% during the third quarter. Vestcor Inc now owns 59,789 shares of the biotechnology company’s stock valued at $1,552,000 after buying an additional 722 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.